Not applicableUnknownINTERVENTIONAL
Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis
ClinicalTrials.gov · NCT05617664 · Registry updated: 2023-08-03
- Condition / research focus
- Nocturnal Enuresis
- Sponsor
- Benha University
- Countries with listed sites
- Egypt
- Registry dates and results
- Start: 2022-11-23. Completion: 2023-10 (may be estimated). No results posted in this registry response.
Products and interventions (3)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- desmopressin 120 mcg oral tablets (drug)
- Mirabegron 25 MG Oral Tablet, Extended Release (drug)
- behavioral therapy alone (behavioral)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Benha University Hospitals
Banhā, Qaliopia, Egypt
Site recruitment: Recruiting